Adicet Bio Inc Ordinary Shares ACET
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
-
Adicet Bio Announces Positive Safety and Efficacy Data from Prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis
-
Adicet Bio to Host Webcast to Present Prula-cel (formerly ADI-001) Clinical Data in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis
-
Adicet Bio to Participate in Fireside Chat at H.C. Wainwright 28th Annual Global Investment Conference
-
Adicet Bio Announces Completion of Last Patient Visit for Planned Analysis of prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus With or Without Lupus Nephritis and Provides Corporate Update
-
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
-
Adicet Bio Gets FDA Clearance For Phase 1 Trial of Prostate Cancer Treatment
-
Adicet Bio Announces FDA Clearance of IND Application for ADI-212
Trading Information
- Previous Close Price
- $6.64
- Day Range
- $6.50–6.82
- 52-Week Range
- $6.01–17.44
- Bid/Ask
- $6.50 / $6.75
- Shares Outstanding
- 9.36M
- Market Cap
- $60.85M
- Volume/Avg
- 164,978 / 161,803
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 102
- Website
- https://www.adicetbio.com
Valuation
|
Metric
|
ACET
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.52 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
ACET
Financial Strength
|
Metric
|
ACET
|
|---|---|
Quick Ratio | 6.59 |
Current Ratio | 6.71 |
Interest Coverage | −1,283.41 |
Quick Ratio
ACET
Profitability
|
Metric
|
ACET
|
|---|---|
Return on Assets (Normalized) | −55.54% |
Return on Equity (Normalized) | −68.24% |
Return on Invested Capital (Normalized) | −64.27% |
Return on Assets
ACET
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|&J!#sC | LOCK|zP<<< | $128B | |||
| Moderna Inc
MRNA
| LOCK|^?d@bWj | LOCK|xC | $76B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|@x!L$# | LOCK|K>tvs | $76B | |||
| argenx SE ADR
ARGX
| LOCK|@GgJwB^ | LOCK|!R | $57B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|k^>l$vK | LOCK|>xq | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|$pYzln | LOCK|>j<V | $29B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|dy$TJ%%f | LOCK|?<TC# | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|Hrkx$?y | LOCK|M? | $24B | |||
| Incyte Corp
INCY
| LOCK|Vn#NSp | LOCK|wc | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|&^><wc | LOCK|&# | $15B |
United States